Michel Darnaud

Ceragenix Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on infectious disease and dermatology. It offers two base technologies: Ceragenins and Barrier Repair. The Ceragenins is used for the treatment of infectious disease and Barrier Repair Technology is used for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders and others. The company was founded in 2002 and is headquartered in Denver, CO.

Diagnostica Stago, Inc. provides medical, dental and hospital equipment. It serves the clinical and research hemostasis laboratory communities. The firms products are viscosity based detection system, reagents, instruments and accessories. The company is located in Parsippany, NJ.

Stentys SA engages in the design, development, and marketing of self-expanding stents used in treating cardiovascular diseases. It provides solutions for the treatment of acute myocardial infarction and other complex coronary diseases. Its products include Xposition S, Devoir, AmazoniaSir, stemiCath, Yangtzenano and YangtzeNC. The company was founded by Gonzague Issenmann and Jacques Seguin on July 6, 2006 and is headquartered in Neuilly-sur-Seine, France.

Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland.